Stereotactic Re-irradiation for Recurrence of Breast Cancer in Lymph Nodes - Report - MDSpire

Stereotactic Re-irradiation for Recurrence of Breast Cancer in Lymph Nodes

  • By

  • Zied Fessi

  • Salomé Bonnier

  • Kaoutar Lodyga

  • Jennifer Wallet

  • Maël Barthoulot

  • Chloé Delerue

  • Pauline Lemoine

  • Paul Archer

  • Marie Dworczak

  • David Pasquier

  • December 8, 2025

  • 0 min

Share

Clinical Report: Stereotactic Re-irradiation for Recurrence of Breast Cancer in Lymph Nodes

Overview

This study evaluates the feasibility and toxicity profile of stereotactic body radiotherapy (SBRT) for nodal recurrence in breast cancer. Findings indicate that SBRT can be effectively utilized in selected patients with isolated lymph node recurrence, showing promising clinical outcomes.

Background

Lymph node recurrence in breast cancer is linked to poor prognosis and increased risk of metastatic disease. The management of locoregional recurrences often involves complex treatment strategies, including re-irradiation. Stereotactic techniques have emerged as a potential option for improving local control while minimizing toxicity in patients with previously irradiated areas.

Data Highlights

Remove placeholder text and include relevant numerical data or state explicitly that data is not available.

Key Findings

Rephrase findings for clarity and ensure they are directly supported by the source material.

Clinical Implications

Healthcare professionals should consider SBRT as a viable treatment option for patients with isolated lymph node recurrence in breast cancer, particularly when previous radiation has been administered. Careful planning and consideration of dose constraints are essential to minimize toxicity.

Conclusion

Stereotactic re-irradiation presents a promising approach for managing nodal recurrences in breast cancer, with acceptable toxicity profiles when meticulously planned. Further studies are warranted to establish long-term outcomes and optimize treatment protocols.

References

  1. Oscar Lambret Center, BMC Cancer, 2025 -- Stereotactic re-irradiation for lymph node recurrence of breast cancer
  2. The ASCO Post — Breast-Conserving Surgery and Partial-Breast Reirradiation in Patients With Ipsilateral Disease Recurrence
  3. The ASCO Post — Breast-Conserving Surgery and Partial-Breast Reirradiation in Patients With Ipsilateral Disease Recurrence
  4. The ASCO Post — Breast-Conserving Therapy May Be a Treatment Option for Some Patients With Multiple Ipsilateral Breast Lesions
  5. the asco post — Regional Nodal Irradiation in Node-Negative Breast Cancer After Neoadjuvant Chemotherapy
  6. Breast-Conserving Surgery and Partial-Breast Reirradiation in Patients With Ipsilateral Disease Recurrence
  7. Breast-Conserving Therapy May Be a Treatment Option for Some Patients With Multiple Ipsilateral Breast Lesions
  8. ESMO International Consensus Guidelines for Advanced Breast Cancer
  9. Stereotactic re-irradiation for lymph node recurrence of breast cancer | BMC Cancer | Springer Nature Link
  10. Results of NRG-BR002 Trial Point to Need for Additional Research of Local Therapy for Oligometastatic Breast Cancer | OncLive

Original Source(s)

Stereotactic Re-irradiation for Recurrence of Breast Cancer in Lymph Nodes

  • by Zied Fessi, Salomé Bonnier, Kaoutar Lodyga, Jennifer Wallet, Maël Barthoulot, Chloé Delerue, Pauline Lemoine, Paul Archer, Marie Dworczak, David Pasquier

  • December 8, 2025

Related Content

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2